{"id":2244,"date":"2020-05-21T19:19:08","date_gmt":"2020-05-21T19:19:08","guid":{"rendered":"https:\/\/mirm-pitt.net\/technologies\/?post_type=avada_portfolio&p=2244"},"modified":"2020-07-08T19:54:21","modified_gmt":"2020-07-08T19:54:21","slug":"endogenous-neogenesis-of-beta-cells","status":"publish","type":"avada_portfolio","link":"https:\/\/mirm-pitt.net\/technologies\/patents\/endogenous-neogenesis-of-beta-cells\/","title":{"rendered":"Endogenous Neogenesis Of Beta Cells"},"content":{"rendered":"

Endogenous Neogenesis Of Beta Cells<\/h2>\n<\/div>
<\/div><\/div><\/div>

Inventors:<\/strong> George Gittes: Ping Guo: Xiangwei Xiao<\/p>\n

Patent Number:<\/strong> 10,071,172<\/p>\n

\n
\n
\n

Abstract<\/h3>\n
\n
\n
Methods are disclosed for producing pancreatic beta cells in a subject. The methods include administering to the subject a vector encoding heterologous Pancreas duodenal homeobox protein (Pdx) 1 and MafA, wherein the vector does not encode Neurogenin 3 (Ngn3) and wherein the subject is not administered any other nucleic acid encoding Ngn3. The vector is administered intraductally into a pancreatic duct of the subject. Compositions are disclosed that include a) a viral vector comprising a promoter operably linked to a nucleic acids encoding Pdx1 and a nucleic acid encoding MafA, wherein the vector does not encode Ngn3; b) a buffer; and c) a contrast dye for endoscopic retrograde cholangiopancreatography. These compositions are of use in any of the methods disclosed herein.<\/div>\n<\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>
<\/div>
<\/div>
<\/div>